Insider trading of Christopher J Coughlin, a Director at AGN Allergan plc.
Most recently Christopher J Coughlin bought 10,000 shares worth $1,633,000.00 on 5 December 2017.
About Allergan plc.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
- Allergan plc., Clonshaugh Business and Technology Park, Dublin D17 E400, Ireland
- 862 261 7000
Insider trading of Christopher J Coughlin, a Director at ALXN Alexion Pharmaceuticals, Inc.
Most recently Christopher J Coughlin bought 2,000 shares worth $234,200.00 on 15 June 2017.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
- Alexion Pharmaceuticals, Inc., 100 College Street, New Haven 06510, United States
Insider trading of Christopher J Coughlin, a Director at HOLX Hologic, Inc.
Most recently Christopher J Coughlin exercised 2,427 shares worth $0.00 on 8 March 2017.
About Hologic, Inc.
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test. The Breast Health segment offers breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. This segment also provides Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View that provides a 2D image; Selenia digital mammography platform; and SecurView Workstation. The GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patients extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
- Hologic, Inc., 250 Campus Drive, Marlborough 01752, United States
Insider trading of Christopher J Coughlin, a Director at DNB Dun & Bradstreet Corporation (The)
Most recently Christopher J Coughlin exercised 2,086 shares worth $183,651.44 on 26 January 2017.
The Dun & Bradstreet Corporation provides commercial data, analytics, and insights on businesses worldwide. It offers risk management solutions, including DNBi and D&B Credit, which are subscription based online applications that provide customers real time access to global information, monitoring, and portfolio analysis; various business information reports; D&B Direct, an application programming interface that enables data integration inside enterprise resource planning applications, and master data management and toolkit; credit monitoring solutions; Supplier Risk Manager, an online application, which helps businesses to mitigate supply chain risk; and Onboard and Compliance Check that are online applications that help customers comply with anti-money laundering. The company also offers sales and marketing solutions, such as customer data management solutions to clean, identify, link, and enrich customer information; D&B Optimizer solution that transforms customer prospects and data into commercial insight; Hoover's that provides information on public and private companies, industries and executives, sales, and marketing and research professionals; Market Insight tools that enable customers to understand existing customers in order to create campaigns to cross-sell new business; Audience Solutions, which enable advertisers and companies to target professionals in various ways; and various other marketing solutions. It serves customers in communication, technology, government, strategic financial service, and retail/telecommunications/manufacturing markets. The Dun & Bradstreet Corporation was founded in 1841 and is headquartered in Short Hills, New Jersey.
- Dun & Bradstreet Corporation (The), 103 JFK Parkway, Short Hills 07078, United States